153 related articles for article (PubMed ID: 35699772)
1. Natural history of MRI brain volumes in patients with neuronal ceroid lipofuscinosis 3: a sensitive imaging biomarker.
Hochstein JN; Schulz A; Nickel M; Lezius S; Grosser M; Fiehler J; Sedlacik J; Löbel U
Neuroradiology; 2022 Oct; 64(10):2059-2067. PubMed ID: 35699772
[TBL] [Abstract][Full Text] [Related]
2. Volumetric Description of Brain Atrophy in Neuronal Ceroid Lipofuscinosis 2: Supratentorial Gray Matter Shows Uniform Disease Progression.
Löbel U; Sedlacik J; Nickel M; Lezius S; Fiehler J; Nestrasil I; Kohlschütter A; Schulz A
AJNR Am J Neuroradiol; 2016 Oct; 37(10):1938-1943. PubMed ID: 27231226
[TBL] [Abstract][Full Text] [Related]
3. Hippocampal volumes in juvenile neuronal ceroid lipofuscinosis: a longitudinal magnetic resonance imaging study.
Tokola AM; Salli EK; Åberg LE; Autti TH
Pediatr Neurol; 2014 Feb; 50(2):158-63. PubMed ID: 24411222
[TBL] [Abstract][Full Text] [Related]
4. JNCL patients show marked brain volume alterations on longitudinal MRI in adolescence.
Autti TH; Hämäläinen J; Mannerkoski M; Van Leemput KV; Aberg LE
J Neurol; 2008 Aug; 255(8):1226-30. PubMed ID: 18677643
[TBL] [Abstract][Full Text] [Related]
5. Expanding the Neuroimaging Phenotype of Neuronal Ceroid Lipofuscinoses.
Biswas A; Krishnan P; Amirabadi A; Blaser S; Mercimek-Andrews S; Shroff M
AJNR Am J Neuroradiol; 2020 Oct; 41(10):1930-1936. PubMed ID: 32855186
[TBL] [Abstract][Full Text] [Related]
6. Quantitative t2 measurements in juvenile and late infantile neuronal ceroid lipofuscinosis.
Paniagua Bravo A; Forkert ND; Schulz A; Löbel U; Fiehler J; Ding X; Sedlacik J; Rosenkranz M; Goebell E
Clin Neuroradiol; 2013 Sep; 23(3):189-96. PubMed ID: 23263384
[TBL] [Abstract][Full Text] [Related]
7. A novel deletion variant in CLN3 with highly variable expressivity is responsible for juvenile neuronal ceroid lipofuscinoses.
Gilani N; Razmara E; Ozaslan M; Abdulzahra IK; Arzhang S; Tavasoli AR; Garshasbi M
Acta Neurol Belg; 2021 Jun; 121(3):737-748. PubMed ID: 33783722
[TBL] [Abstract][Full Text] [Related]
8. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
[TBL] [Abstract][Full Text] [Related]
9. FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis.
Goodkin O; Prados F; Vos SB; Pemberton H; Collorone S; Hagens MHJ; Cardoso MJ; Yousry TA; Thornton JS; Sudre CH; Barkhof F;
Neuroimage Clin; 2021; 29():102542. PubMed ID: 33418171
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
Margoni M; Pagani E; Preziosa P; Gueye M; Azzimonti M; Rocca MA; Filippi M
J Neurol; 2023 Aug; 270(8):3839-3850. PubMed ID: 37093395
[TBL] [Abstract][Full Text] [Related]
11. An Ophthalmic Rating Scale to Assess Ocular Involvement in Juvenile CLN3 Disease.
Dulz S; Atiskova Y; Wibbeler E; Wildner J; Wagenfeld L; Schwering C; Nickel M; Bartsch U; Spitzer MS; Schulz A
Am J Ophthalmol; 2020 Dec; 220():64-71. PubMed ID: 32707205
[TBL] [Abstract][Full Text] [Related]
12. Following the Spreading of Brain Structural Changes in Alzheimer's Disease: A Longitudinal, Multimodal MRI Study.
Weiler M; Agosta F; Canu E; Copetti M; Magnani G; Marcone A; Pagani E; Balthazar ML; Comi G; Falini A; Filippi M
J Alzheimers Dis; 2015; 47(4):995-1007. PubMed ID: 26401778
[TBL] [Abstract][Full Text] [Related]
13. The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.
Lie IA; Kerklingh E; Wesnes K; van Nederpelt DR; Brouwer I; Torkildsen Ø; Myhr KM; Barkhof F; Bø L; Vrenken H
Eur Radiol; 2022 May; 32(5):3576-3587. PubMed ID: 34978580
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of Deep Gray Matter Atrophy Rate Measurement in a Large Multicenter Dataset.
Meijerman A; Amiri H; Steenwijk MD; Jonker MA; van Schijndel RA; Cover KS; Vrenken H;
AJNR Am J Neuroradiol; 2018 Jan; 39(1):46-53. PubMed ID: 29191870
[TBL] [Abstract][Full Text] [Related]
15. Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
Meijboom R; York EN; Kampaite A; Harris MA; White N; Valdés Hernández MDC; Thrippleton MJ; MacDougall NJJ; Connick P; Hunt DPJ; Chandran S; Waldman AD;
PLoS One; 2023; 18(7):e0288967. PubMed ID: 37506096
[TBL] [Abstract][Full Text] [Related]
16. Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI.
Meier DS; Guttmann CRG; Tummala S; Moscufo N; Cavallari M; Tauhid S; Bakshi R; Weiner HL
J Neuroimaging; 2018 Jan; 28(1):36-47. PubMed ID: 29235194
[TBL] [Abstract][Full Text] [Related]
17. MRI evaluation of the brain in infantile neuronal ceroid-lipofuscinosis. Part 2: MRI findings in 21 patients.
Vanhanen SL; Raininko R; Autti T; Santavuori P
J Child Neurol; 1995 Nov; 10(6):444-50. PubMed ID: 8576553
[TBL] [Abstract][Full Text] [Related]
18. MRI Brain Volume Measurements in Infantile Neuronal Ceroid Lipofuscinosis.
Baker EH; Levin SW; Zhang Z; Mukherjee AB
AJNR Am J Neuroradiol; 2017 Feb; 38(2):376-382. PubMed ID: 27765741
[TBL] [Abstract][Full Text] [Related]
19. Gray and white matter are both affected in classical galactosemia: An explorative study on the association between neuroimaging and clinical outcome.
Welsink-Karssies MM; Schrantee A; Caan MWA; Hollak CEM; Janssen MCH; Oussoren E; de Vries MC; Roosendaal SD; Engelen M; Bosch AM
Mol Genet Metab; 2020 Dec; 131(4):370-379. PubMed ID: 33199205
[TBL] [Abstract][Full Text] [Related]
20. Evaluating anorexia-related brain atrophy using MP2RAGE-based morphometry.
Boto J; Gkinis G; Roche A; Kober T; Maréchal B; Ortiz N; Lövblad KO; Lazeyras F; Vargas MI
Eur Radiol; 2017 Dec; 27(12):5064-5072. PubMed ID: 28639048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
